The last patient enrolled in Immuron's IMM-124E phase II study completed their final visit. Results from the trial could be available as soon as the first quarter of 2018.
Here's what you should know:
1. Immuron conducted its last clinical visit on Oct. 9, and its final close-out visit on Oct. 18, following 28 weeks of study and observation.
2. Immuron studied a total of 133 nonalcoholic fatty liver disease patients.
3. The company expects to report top-line results once the data is finalized and reviewed by its Scientific Advisory Board.
4. The company disclosed interim results of 122 patients in July 2017. In these patients IMM-124E caused a statistically significant reduction in the ALT enzyme over time when compared to a placebo.
Immuron CEO Jerry Kanellos said in a release, "The completion of these patient studies marks a pivotal inflection point for Immuron, as we now look forward to analysing and reporting the data results."